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Antimicrobial peptides are a diverse family of small, mostly cationic polypeptides that kill bacteria, fungi and even some enveloped viruses,
while chemokines are a group of mostly cationic small proteins that induce directed migration of leukocytes through interactions with a group of
seven transmembrane G protein-coupled receptors. Recent studies have shown that antimicrobial peptides and chemokines have substantially
overlapping functions. Thus, while some antimicrobial peptides are chemotactic for leukocytes, some chemokines can kill a wide range of bacteria
and fungi. Here, we examined a possible direct antiviral activity of chemokines against an enveloped virus HSV-1. Among 22 human chemokines
examined, chemokines such as MIP-1α/CCL3, MIP-1β/CCL4 and RANTES/CCL5 showed a significant direct antiviral activity against HSV-1. It
is intriguing that these chemokines are mostly known to be highly expressed by effector CD8+ T cells. The chemokines with a significant anti-
HSV-1 activity commonly bound to HSV-1 virions via envelope glycoprotein gB. Electron microscopy revealed that the chemokines with a
significant anti-HSV-1 activity were commonly capable of generating pores in the envelope of HSV-1. Thus, some chemokines have a significant
direct antiviral activity against HSV-1 in vitro and may have a potential role in host defense against HSV-1 as a direct antiviral agent.
© 2006 Elsevier Inc. All rights reserved.Keywords: Chemokines; Antiviral; HSV-1; gB; Antimicrobial peptidesIntroduction
Antimicrobial peptides, now known by >500 in number, are
a diverse family of small, mostly cationic polypeptides that can
kill bacteria, fungi, and even some enveloped viruses
(Clayberger and Krensky, 2003; Daher et al., 1986; Ganz,
2003; Howell et al., 2004; Wang et al., 2003; Zasloff, 2002). In
mammals, such peptides are particularly abundant in the storage
granules of phagocytic cells, cytotoxic granules of lympho-
cytes, and on the surface of mucosal tissues (Clayberger and
Krensky, 2003; Ganz, 2003; Zasloff, 2002). Chemokines are a
group of mostly highly cationic small proteins that induce
directed migration of various leukocytes through interactions⁎ Corresponding author. Fax: +81 72 367 3606.
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doi:10.1016/j.virol.2006.03.004with a group of seven transmembrane G protein-coupled
receptors (Yoshie et al., 2001; Zlotnik and Yoshie, 2000).
Previous studies have shown that, like antimicrobial peptides, a
number of chemokines have a potent direct killing activity
against bacteria and fungi (Cole et al., 2001; Hieshima et al.,
2003; Krijgsveld et al., 2000; Starner et al., 2003; Tang et al.,
2002; Yang et al., 2003). For example, we have shown that
CCL28 (also known as mucosae-associated chemokine) (Pan et
al., 2000; Wang et al., 2000), which is selectively expressed at
high levels in the mucosal tissues such as parotid glands,
trachea, and colon, is secreted at high concentrations into low-
salt body fluids such as saliva and milk and has a significant
antimicrobial activity against a wide range of bacteria and fungi
(Hieshima et al., 2003). Thus, CCL28 may have a dual role in
mucosal immunity by recruiting IgA-producing plasma cells
into the lamina propria of target mucosal tissues via its receptor
CCR10 (Hieshima et al., 2003, 2004; Kunkel et al., 2003;
Table 1
Summary of anti-HSV-1 activity of chemokines
Chemokine IC50 (μM)
PBS 1/10 PBS
Most potent
MIP-1α/CCL3 1.5 ± 0.3 0.3 ± 0.1
MIP-1β/CCL4 1.0 ± 0.2 0.2 ± 0.1
RANTES/CCL5 0.8 ± 0.1 0.2 ± 0.1
Intermediate
Eotaxin/CCL11 2.9 ± 0.1 0.5 ± 0.1
PF4/CXCL4 4.3 ± 0.4 0.9 ± 0.1
MIG/CXCL9 4.6 ± 0.2 0.9 ± 0.1
SDF-1/CXCL12 4.3 ± 0.5 0.7 ± 0.2
lymphotactin/XCL1 3.9 ± 0.6 0.6 ± 0.1
Weak or negative
MCP-1/CCL2 >10 ND
LEC/CCL16 >10 ND
TARC/CCL17 >10 ND
PARC/CCL18 >10 ND
ELC/CCL19 >10 ND
LARC/CCL20 >10 ND
SLC/CCL21 >10 ND
MDC/CCL22 >10 ND
TECK/CCL25 >10 ND
MEC/CCL28 >10 ND
Gro-α/CXCL1 >10 ND
IL-8/CXCL8 >10 ND
IP-10/CXCL10 >10 ND
CXCL16 >10 ND
HSV-1 was treated at 37 °C for 1 h with each chemokine serially diluted in PBS
or 1/10 PBS containing 0.1% BSA. After that, viral titers were determined by a
standard plaque assay on Vero cells to obtain IC50. Data represent mean ± SEM
from at least three independent experiments. The results in this table are all from
the recombinant chemokines obtained from R&D Systems. However, CCL2,
CCL3, CCL4 and CCL5 obtained from Peprotech also gave essentially the same
results (data not shown).
485T. Nakayama et al. / Virology 350 (2006) 484–492Lazarus et al., 2003; Wilson and Butcher, 2004) and also by
exerting a broad-spectrum antimicrobial activity in secreted
body fluids (Hieshima et al., 2003). Conversely, someFig. 1. Specific binding of HSV-1 to the chemokines with anti-HSV-1 activity.
(A) Measurement of HSV-1 bound to immobilized chemokines. Aliquots of
HSV-1 (1 × 107 PFU/ml in PBS) were applied to wells (50 μl/well) pre-coated
with indicated chemokines and incubated at 37 °C for 1 h. After washing, bound
HSV-1 virions were recovered and measured by real-time PCR. For details, see
Materials and methods. All assays were done in triplicate. Representative results
from three separate experiments are shown. Horizontal bars indicate SEM. (B)
Inhibition of HSV-1 binding to RANTES/CCL5 by anti-gB MAb. Aliquots of
HSV-1 (1 × 107 PFU/ml in PBS) were pretreated at room temperature for 15 min
without or with anti-gB, anti-gC, anti-gD, anti-gE, anti-gG, anti-gP or mouse
control IgG at 10 μg/ml and then applied to wells (50 μl/well) pre-coated with
RANTES/CCL5. After washing, bound HSV-1 virions were removed and
measured by real-time PCR. Representative results from three separate
experiments are shown. Horizontal bars indicate SEM. (C) Inhibition of HSV-
1 binding to anti-HSV-1 chemokines by anti-gB MAb. Aliquots of HSV-1
(1 × 107 PFU/ml in PBS) were pretreated at room temperature for 15 min with
anti-gB MAb or mouse control IgG at 10 μg/ml and then applied to wells (50 μl/
well) precoated with indicated chemokines. After washing, bound HSV-1
virions were removed and measured by real-time PCR. Representative results
from three separate experiments are shown. Horizontal bars indicate SEM.antimicrobial peptides have been shown to have a potent
chemotactic activity for various blood leukocytes. For example,
β-defensins attract dendritic cells and Tcells through interaction
with a chemokine receptor CCR6 (Yang et al., 1999). LL-37
(the neutrophil granule- and epithelial cell-derived cathelicidin)
attracts neutrophils, monocytes and T cells via formyl peptide
receptor-like 1 (FPRL1), a serpentine receptor closely related to
the chemokine receptors (De et al., 2000). It is thus possible that
Fig. 2. Specific binding of recombinant HSV-1 gB to the chemokines with anti-
HSV-1 activity. (A) Specific binding of gB-SEAP(His)6 to RANTES/CCL5.
Indicated concentrations of gB-SEAP(His)6 (a) or gD-SEAP(His)6 (b) were
applied to wells (50 μl/well) pre-coated without (○) or with RANTES/CCL5
(•) and incubated at room temperature for 1 h. After washing, bound SEAP
fusion proteins were measured by the alkaline phosphatase enzymatic activity
and expressed by relative light units/s. For details, see Materials and methods.
Each point represents mean ± SEM from three separate experiments. (B)
Specific binding of gB-SEAP(His)6 to the chemokines with anti-HSV-1 activity.
gB-SEAP(His)6 was applied at 20 nM to wells (50 μl/well) pre-coated without
or with indicated chemokines and incubated at room temperature for 1 h. After
washing, bound gB-SEAP(His)6 was measured by the alkaline phosphatase
activity and expressed as relative light units/s. For details, see Materials and
methods. Each point represents ± SEM from three separate experiments.
486 T. Nakayama et al. / Virology 350 (2006) 484–492chemokines and antimicrobial peptides have substantially
overlapping functions. At present, it is not known whether
such close functional relationships between chemokines and
antimicrobial peptides have an evolutionary basis (Yang et al.,
2002).
Given that some antimicrobial peptides have a direct
antiviral activity against some enveloped viruses (Daher et al.,
1986; Howell et al., 2004; Wang et al., 2003), we asked whether
some chemokines might have a direct antiviral activity against
an enveloped virus. Here, we report that some chemokines,
especially MIP-1α/CCL3, MIP-1β/CCL4 and RANTES/CCL5
that are all highly expressed by effector CD8+ T cells and NK
cells (Catalfamo et al., 2004; Cocchi et al., 1995; Dorner et al.,
2002, 2004; Stievano et al., 2003; Swanson et al., 2002; Wagner
et al., 1998; Walzer et al., 2003), can directly inactivate HSV-1
through binding to its envelope glycoprotein gB.
Results
Inactivation of HSV-1 by chemokines
We tested a total of 22 human chemokines for possible direct
inactivation of HSV-1. HSV-1 was treated at 37 °C for 1 h with
each chemokine in PBS containing 0.1% BSA. Then, the viral
titers were determined by a standard plaque assay on Vero cells.
The results are summarized in Table 1. As many as eight
chemokines reduced HSV-1 titers with an IC50 less than 10 μM.
These were MIP-1α/CCL3, MIP-1β/CCL4, RANTES/CCL5,
eotaxin/CCL11, PF-4/CXCL4, MIG/CXCL9, SDF-1/CXCL12
and lymphotactin/XCL1. In particular, MIP-1α/CCL3, MIP-1β/
CCL4 and RANTES/CCL5 were most potent in anti-HSV-1
activity. In control experiments, we observed no reduction in
HSV-1 titers by pretreating Vero cells with 10 μM of each
chemokine at 37 °C for 1 h prior to plaque assays (data not
shown). We also confirmed that each chemokine at 10 μM had
no cytotoxic or other adverse effects on Vero cells by 24 h (data
not shown). Thus, it was likely that some chemokines could
directly inactivate HSV-1.
In general, a low-salt condition is essential for the
bacteriocidal activity of antimicrobial peptides and chemokines
(Cole et al., 2001; Ganz, 2003; Hieshima et al., 2003;
Krijgsveld et al., 2000; Starner et al., 2003; Tang et al., 2002;
Yang et al., 2003). Therefore, we also determined IC50 of the
eight chemokines in 1/10 PBS. All the chemokines indeed
showed a 4- to 6-fold reduction in IC50 in a low salt condition
(Table 1). Nevertheless, the anti-HSV-1 activity of these
chemokines was obviously less sensitive to salt concentrations
than the usual antimicrobial activities of antimicrobial peptides
and chemokines. This suggested that the binding of these
chemokines to HSV-1 was not simply through the electrostatic
interactions.
Direct binding of HSV-1 with anti-HSV-1 chemokines
If some chemokines were capable of directly inactivating
HSV-1, these chemokines should be able to bind to HSV-1
virions. To test this, aliquots of HSV-1 were added to ELISAplates pre-coated with various chemokines and incubated at
37 °C for 1 h. After washing, bound HSV-1 virions were
recovered with a lysis buffer containing 0.5% NP-10 and
measured by real-time PCR using primers specific for HSV-1
UL30 gene. As shown in Fig. 1A, HSV-1 virions indeed
selectively bound to the chemokines that showed a significant
anti-HSV-1 activity (Table 1). To further examine the viral
components that were involved in HSV-1 binding to RANTES/
487T. Nakayama et al. / Virology 350 (2006) 484–492CCL5, we pretreated HSV-1 virions with MAbs to various
HSV-1 envelope glycoproteins prior to the binding assay. As
shown Fig. 1B, only anti-gBMAb significantly reduced binding
of HSV-1 virions to RANTES/CCL5. Furthermore, as shown in
Fig. 1C, the binding of HSV-1 virions to other seven anti-HSV-1
chemokines was also significantly reduced by anti-gB MAb.
This suggested that the chemokines with anti-HSV-1 activity
were commonly capable of binding to HSV-1 via gB.
Direct binding of recombinant HSV-1 gB to chemokines
To directly test the binding of HSV-1 gB to chemokines, we
generated recombinant proteins consisting of the ectodomains
of gB and gD fused with the secreted form of alkaline
phosphatase (SEAP) tagged with six histidine residues (Imai et
al., 1997). The proteins were termed gB-SEAP(His)6 and gD-
SEAP(His)6, respectively. These recombinant proteins were
applied to immobilized RANTES/CCL5 and bound proteins
were measured by their SEAP activity. As shown in Fig. 2A(a),
gB-SEAP(His)6 specifically bound to RANTES/CCL5. On the
other hand, as shown in Fig. 2A(b), gD-SEAP(His)6 or control
SEAP(His)6 (not shown) did not bind to RANTES/CCL5 at all.
Fig. 2B further shows that gB-SEAP(His)6 also bound to other
seven anti-HSV-1 chemokines but not to a negative control
MCP-1/CCL2. Collectively, the chemokines with a significant
anti-HSV-1 activity were commonly capable of binding to HSV-
1 envelope glycoprotein gB.Fig. 3. Analysis of HSV-1 treated with chemokines with electron microscopy. Aliquo
1 μM at 37 °C for 1 h. After that, samples were appropriately processed and observed
For details, see Materials and methods. Scale bars shown in control panels are 100 n
virions treated with chemokines. At least 200 virions were randomly examined from e
severely damaged virions. Each point represents mean ± SEM from three separate eElectron microscopic observation of HSV-1 virions treated with
chemokines
To further gain an insight into the mode of action of
chemokines with anti-HSV-1 activity on HSV-1 virions, we
examined the morphology of HSV-1 virions treated with
chemokines at 1 μM at 37 °C for 1 h. Scanning electron
microscopy (Fig. 3A) as well as transmission electron
microscopy (Fig. 3B) revealed that the majority of viral
particles treated with PBS alone or with MCP-1/CCL2 (the
negative control) were intact, showing smooth surface, but
damaged viral particles were dramatically increased in the virus
samples treated with MIP-1α/CCL3, MIP-1β/CCL4, or
RANTES/CCL5. In particular, virus particles with pores in
the envelope were rarely seen in the control samples, but were
dramatically increased in the samples treated with MIP-1α/
CCL3, MIP-1β/CCL4, or RANTES/CCL5. We therefore
determined the frequencies of intact virions, virions with
pores, and those severely damaged by counting more than 200
virions for each sample. The results are summarized in Fig. 3C.
While about 70–80% of virions were intact in the samples
treated with PBS or MCP-1/CCL2 (the negative control), only
about 20% of virions were intact in the samples treated with
MIP-1α/CCL3, MIP-1β/CCL4, or RANTES/CCL5. On the
other hand, the frequencies of virions with pores and severely
damaged virions were dramatically increased in the samples
treated with MIP-1α/CCL3, MIP-1β/CCL4, or RANTES/ts of HSV-1 (15 μl, 1 × 1011 PFU/ml) were treated without or with chemokines at
by scanning electron microscopy (A) and transmission electron microscopy (B).
m. Arrows indicate holes in the viral envelope. (C) Differential counting HSV-1
ach sample to make a differential count of intact virions, virions with pores, and
xperiments.
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samples treated with PBS alone or MCP-1/CCL2 (the negative
control) but were dramatically increased to about 30–40% in the
samples treated with MIP-1α/CCL3, MIP-1β/CCL4, or
RANTES/CCL5. It is thus likely that anti-HSV-1 chemokines
primarily generate pores in the HSV-1 envelope, which lead to
further disintegration of the virus particles.
Discussion
Recent studies have demonstrated that chemokines and
antimicrobial peptides have substantially overlapping func-
tions, even though the evolutionary basis of these findings is
not clear yet (Yang et al., 2002). Thus, some chemokines have
a significant antimicrobial activity against a wide range of
bacteria and fungi (Cole et al., 2001; Hieshima et al., 2003;
Krijgsveld et al., 2000; Starner et al., 2003; Tang et al., 2002;
Yang et al., 2002, 2003), while some antimicrobial peptides are
chemotactic for blood leukocytes (De et al., 2000; Yang et al.,
1999). Concerning antiviral activity, some antimicrobial
peptides have been shown to directly inactivate some
enveloped viruses (Daher et al., 1986; Howell et al., 2004;
Wang et al., 2003). Furthermore, α-defensins 1, 2 and 3 have
been shown to inhibit replication, not entry, of HIV-1 in host
cells (Chang et al., 2005; Zhang et al., 2002). In the case of
chemokines, MIP-1α/CCL3, MIP-1β/CCL4 and RANTES/
CCL5 are known to be released by CD8+ T cells and suppress
infection of R5-type HIV-1 by blocking the use of CCR5
coreceptor (Cocchi et al., 1995; D'Souza and Harden, 1996).
Similarly, SDF-1/CXCL12 is known to inhibit infection of X4-
type HIV-1 by blocking the use of CXCR4 coreceptor (Amara
et al., 1997; Bleul et al., 1996; Oberlin et al., 1996). However,
it has not been shown whether any chemokines have a direct
antiviral activity against some enveloped viruses. Here, we
have demonstrated for the first time that some chemokines
have a significant direct antiviral activity against an enveloped
virus HSV-1 (Table 1).
There are notable discrepancies between the chemokines
with a potent anti-bacterial/fungal activity and those with a
potent anti-HSV-1 activity. While chemokines such as IP-10/
CXCL10, MEC/CCL28 and LARC/CCL20 have been reported
to be most potent in killing bacteria and fungi (Cole et al., 2001;
Hieshima et al., 2003; Yang et al., 2003), these chemokines are
essentially negative for anti-HSV-1 activity in the present study
(Table 1). On the other hand, chemokines such as MIP-1α/
CCL3, MIP-1β/CCL4 and RANTES/CCL5 have been shown to
be essentially negative for bactericidal activity (Cole et al.,
2001; Hieshima et al., 2003; Yang et al., 2003), but are most
potent in anti-HSV-1 activity in the present study (Table 1).
Furthermore, even though cationic net charges are considered to
be important for the antimicrobial activity of chemokines (Cole
et al., 2001; Hieshima et al., 2003; Krijgsveld et al., 2000;
Starner et al., 2003; Tang et al., 2002; Yang et al., 2003), MIP-
1α/CCL3 and MIP-1β/CCL4 are the exceptional chemokines
that have anionic, not cationic, net charges. These discrepancies
may be partly due to the different mechanisms of binding of
chemokines to bacteria/fungi and to HSV-1 virions.The main target structure of antimicrobial peptides in
bacteria and fungi is the microbial plasma membrane, which,
in contrast to that of mammalian cells, lacks cholesterol and
relatively rich in negatively charged phospholipids (Ganz,
2003; Yang et al., 2002). Thus, antimicrobial peptides, which
are commonly highly cationic, selectively bind to the microbial
plasma membranes by electrostatic interactions. After binding,
these peptides are considered to penetrate the plasma mem-
branes via their hydrophobic regions and to form a channel-like
pore through self-aggregation within the plasma membrane
(Ganz, 2003; Yang et al., 2002). Chemokines, which are also
mostly highly cationic, are likely to bind and damage the
microbial plasma membrane essentially through the same
mechanism (Hieshima et al., 2003; Yang et al., 2003). In the
case of enveloped viruses, however, the viral envelopes are
primarily derived from the membranes of host cells. Thus, there
would be no big differences in the charge or other basic
properties between the viral envelopes and host cell membranes.
This suggests that there should be some specific binding sites in
the viral envelope for antimicrobial peptides and antiviral
chemokines. In this context, Wang et al. have shown that
retrocyclin, an ancestral hominid θ-defensin, protects human
cells from infection by X4- and R5-strains of HIV-1 by binding
to the glycoproteins such as gp120 and CD4 through a lectin-
like activity (Wang et al., 2003). Furthermore, Yasin et al. have
shown that θ-defensin can also protect cells from infection by
HSV-1 by binding to the viral glycoprotein gB (Yasin et al.,
2004). In the present study, we have shown that the chemokines
with a significant anti-HSV-1 activity are also commonly
capable of binding to HSV-1 gB (Figs. 1, 2). HSV-1 gB is a viral
envelope glycoprotein required for efficient virus entry and
known to bind to heparan sulfate proteoglycan on the host cell
surface (Laquerre et al., 1998). Thus, some unique structural
and biochemical features of gB may allow its efficient binding
with θ-defensin and some chemokines. It remains to be seen
which structural and biochemical features of gB account for its
efficient binding with anti-HSV-1 chemokines. After binding to
HSV-1 virions via gB, anti-HSV-1 chemokines apparently
generate pores in the viral envelope (Fig. 3). Thus, these
chemokines may be inserted into the viral envelope by their
hydrophobic regions and may form channel-like pores through
self-aggregation within the membrane. This latter property,
which is probably essential for the bactericidal activity of most
antimicrobial peptides and chemokines, may require a low
micromolar concentration for efficient self-polymerization
within the microbial target membranes (Ganz, 2003; Yang et
al., 2002).
Another notable point with the chemokines with a significant
anti-HSV-1 activity is that MIP-1α/CCL3, MIP-1β/CCL4 and
RANTES/CCL5 are all known to be selectively expressed at
high levels by effector CD8+ T cells and NK cells (Catalfamo et
al., 2004; Cocchi et al., 1995; Dorner et al., 2002, 2004;
Stievano et al., 2003; Swanson et al., 2002; Wagner et al., 1998;
Walzer et al., 2003). These are the exact types of cells known to
play the major roles in innate and acquired immunity against
viruses including HSV-1 (Bishop et al., 1984; Khanna et al.,
2004). Furthermore, Luster and his colleagues have reported
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co-localized with perforin in the cytotoxic granules of CD8+ T
cells and released via granular exocytosis (degranulation) upon
TCR-stimulation of these cells (Wagner et al., 1998). We have
also shown that CD8+ Tcells infiltrating in chronically inflamed
tissues such as oral lichen planus and chronic active gastritis
consistently carry RANTES/CCL5 proteins in cytoplasmic
vesicles resembling the cytotoxic granules (Iijima et al., 2003;
Ohtani et al., 2004). Recently, however, Catalfamo et al. have
reported that RANTES/CCL5, even though released via granule
exocytosis, is stored in cytoplasmic vesicles different from
those of perforin (Catalfamo et al., 2004). At any rate, it is
intriguing that the chemokines with the most potent anti-HSV-1
activity happen to be the ones that are commonly stored in the
cytoplasmic granules of cytotoxic lymphocytes and rapidly
released upon cell activation. Furthermore, CD8+ T cells and
NK cells are known to form the immunological synapse with
their targets (Lieberman, 2003). This would allow the delivery
of their granular contents onto the target surface at very high
concentrations. If the targets are HSV-1 virions or HSV-1-
infected cells expressing HSV-1 gB on the surface, the released
chemokines may directly attack the target virions or infected
cells at high concentrations.
Yet another intriguing point possibly related to the present
finding is that many herpesviruses are known to encode the
viral chemokine receptors that bind and sequester many
chemokines including MIP-1α/CCL3, MIP-1β/CCL4 and
RANTES/CCL5 (Bodaghi et al., 1998; Murphy, 2001).
Currently, the viral chemokine receptors are considered to
have a role in the viral escape strategy by capturing
chemokines released from infected cells and thus preventing
attraction of leukocytes toward infected cells (Bodaghi et al.,
1998; Murphy, 2001). However, another possibility suggested
from the present study may be that the viral chemokine
receptors are also meant to capture chemokines that potentially
cause damages to virions and virus-infected cells and that are
released in close vicinity and at high concentrations by effector
CD8+ T cells and NK cells. Future studies are necessary to
address such possibilities.
The antimicrobial activities of chemokines generally require
much higher concentrations than their optimal concentrations
for induction of leukocyte chemotaxis (Cole et al., 2001;
Hieshima et al., 2003; Krijgsveld et al., 2000; Starner et al.,
2003; Tang et al., 2002; Yang et al., 2003). The levels of
effective concentrations of chemokines for antimicrobial
activity are, however, comparable to those of standard
antimicrobial peptides and considered to be theoretically
attainable at local infection sites (Cole et al., 2001; Hieshima
et al., 2003; Krijgsveld et al., 2000; Starner et al., 2003; Tang et
al., 2002; Yang et al., 2003). The anti-HSV-1 activity of some
chemokines shown here also requires relatively high concentra-
tions (Table 1). For example, the IC50 of RANTES/CCL5 was
0.2–0.8 μMdepending on the salt concentration. It was reported
that the concentration of RANTES/CCL5 in activated CD8+ T
cells could reach 1.6 μg/106 cells (Cocchi et al., 1995). Based
on this assumption, the calculated density of CD8+ T cells
required for 0.2–0.8 μM of RANTES/CCL5 would be 1.3–5.0 × 106 cells/ml. Given the size of CD8+ T cells, these
densities could be easily reached at local infection sites. In
addition, there could be additive and/or synergistic effects
among various effector molecules including chemokines (Tang
et al., 2002). We observed that the chemokines with anti-HSV-1
activity were at least additive in reducing HSV-1 titers (data not
shown).
In conclusion, chemokines such as MIP-1α/CCL3, MIP-1β/
CCL4 and RANTES/CCL5 have a significant direct antiviral
activity against HSV-1 at concentrations that are comparable to
the known effective concentrations of potent antimicrobial
peptides. They can commonly bind to HSV-1 envelope
glycoprotein gB. Furthermore, MIP-1α/CCL3, MIP-1β/CCL4
and RANTES/CCL5 are all known to be stored in the
cytoplasmic granules of effector CD8+ T cells and NK cells
and can be released to the target surface at high concentrations
upon cell activation. Thus, these chemokines may have a
potential role in the host defense against HSV-1 as a direct
antiviral agent. Studies using mice deficient of these chemo-
kines or employing neutralizing antibodies against these
chemokines may be useful to determine their actual contribution
as a direct antiviral agent in vivo. It also remains to be seen
whether some chemokines have a significant antiviral activity
against other enveloped viruses such as cytomegalovirus and
HIV-1.
Materials and methods
Chemokines and antibodies
All recombinant human chemokines were purchased from
R&D systems (Minneapolis, MN). MCP-1/CCL2, MIP-1α/
CCL3, MIP-1β/CCL4 and RANTES/CCL5 were also pur-
chased from PeproTech (Rocky Hill, NJ). Monoclonal anti-
bodies against HSV-1 gB (10B7) and HSV-1 gG (7F5) were
purchased from Virusys Corporation (Sykesvill, MD). Mono-
clonal antibodies against HSV-1 gC, HSV-1 gE and HSV-1 gP
were purchased from ViroStat (Portland, ME). Monoclonal
antibody against HSV-1 gD (1-I-9) was purchased from
Chemicon (Temecula, CA). The McKrae strain of HSV-1 was
propagated in Vero cells as described previously (Hill et al.,
1987; Shirane et al., 2004).
HSV-1
HSV-1 titers were determined by a standard plaque assay
on Vero cells (Oakes et al., 1984; Shirane et al., 2004). In
brief, Vero cells were plated at 5 × 105 cells/well in 6-well
plates and cultured overnight. HSV-1 samples were applied to
wells and incubated at 37 °C for 3 h for virus adsorption.
After washing with phosphate buffered saline (PBS), cells
were placed in 3 ml fresh medium and cultured at 37 °C for
48 h. After washing, cells were fixed with 0.5% glutaralde-
hyde in PBS at room temperature for 10 min and stained with
hematoxylin. Plaques were counted under an inverted
microscope. To test direct inactivation of HSV-1 by
chemokines, HSV-1 was incubated without or with test
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done as described above. The final concentrations of
chemokines in these plaque assays were diluted at least 200-
fold. In some experiments, Vero cells but not HSV-1 were
pretreated with chemokines at 10 μM at 37 °C for 1 h and
washed before the plaque assay.
Binding of HSV-1 to immobilized chemokines
Chemokines (2 μg/ml in H2O) were immobilized onto
ELISA plates at 37 °C for 1 h. After washing, wells were
blocked with PBS containing 1% bovine serum albumin (BSA)
at 37 °C for 30 min. After washing with water, wells were
inoculated with 50 μl of HSV-1 (1 × 107 PFU/ml in PBS). In
some experiments, HSV-1 was pretreated with anti-gB, anti-gC,
anti-gD, anti-gE, anti-gG, anti-gP or control mouse IgG at
10 μg/ml at room temperature for 15 min. After incubation at
37 °C for 1 h and washing with water, bound HSV-1 virions
were lysed with 10 μl of 10 mM Tris–EDTA buffer (pH 7.8)
containing 0.5% NP-40 at room temperature for 20 min. The
lysed HSV-1 was diluted 10-fold with 10 mM Tris–EDTA
buffer (pH 7.8) and was then measured by real-time PCR for
HSV-1 UL30 gene as described previously (Marquart et al.,
2003). In brief, real-time PCR reactions were performed in a
25 μl mixture containing sample DNA (2 μl) and 2× master
mix, and using TaqMan assay and 7700 Sequence Detection
System (Applied Biosystems, Foster City, CA). Conditions for
PCR were 50 °C for 2 min, 95 °C for 10 min, and 50 cycles of
95 °C for 15 s (denaturation) and 60 °C for 1 min (annealing/
extension). Copy numbers were determined by using a standard
curve generated from control HSV-1. The primers used were
+5′-CATCACCGACCCGAGGAGGAC-3′ and −5′-GGGC-
CAGGCGCTTGTTGGTGTA-3′. The probe was 5′-CCGCC-
GAACTGAGCAGACACCCGCGC-3′ that was labeled at the
5′-end with fluorescent reporter dye of 6-FAM. The primers and
probe were purchased from Qiagen (Hilden, Germany).
Quantification of HSV-1 was done by using Sequence Detector
System (Applied Biosystems).
Binding of HSV-1 gB and gD to chemokines
We produced the ectodomain of HSV-1 glycoproteins gB
and gD as fusion proteins with the secreted form of alkaline
phosphatase (SEAP) tagged with six histidine residues (the
(His)6 tag) as described previously (Imai et al., 1997). In
brief, the coding sequences of gB ectodomain comprising 730
amino acids and gD ectodomain comprising 340 amino acids
were amplified from pVF30 (Rosenthal et al., 1987)
(generously provided by Dr. David C. Johnson, Oregon
Health Sciences, University of Portland) and HSV-1
(McKrae) genomic DNA,respectively. The primers used
were: +5′-CATCTCGAGCCCGTAGTCCCGCCATGC-3′
and −5′-CATTCTAGACATGGCGGCGTTGGCGTC-3′
for gB; +5′-CATCTCGAGGTGGTGCGTTCCGGTATG-3′
and −5′-CATTCTAGACATGTTGTTCGGGGTGGC-3′ for
gD. The amplified coding sequences were subcloned into
pDREF-SEAP(His)6-Hyg vector (Imai et al., 1997), gene-rating pDREF-gB-SEAP(His)6-Hyg and pDREF-gD-SEAP
(His)6-Hyg. 293/EBNA-1 cells were transiently transfected
with these plasmids using Lipofectamine (Invitrogen, Carls-
bad, CA). The fusion proteins termed gB-SEAP(His)6 and
gD-SEAP(His)6 were purified from the culture supernatants
using TARON metal affinity resin column (BD Biosciences,
Mountain View, CA). The concentrations of gB-SEAP(His)6
and gD-SEAP(His)6 were determined by a sandwich-type
enzyme-linked immunosorbent assay for alkaline phosphatase
as described previously (Imai et al., 1997). Purified placental
alkaline phosphatase was purchased from Cosmo Bio (Tokyo,
Japan) and used to generate the standard curve.
Chemokines (2 μg/ml in distilled water) were immobilized
onto ELISA plates at 37 °C for 1 h. After washing, plates were
blocked with PBS containing 3% BSA at 37 °C for 30 min.
After washing, 50 μl of PBS containing 0.1% BSA and gB-
SEAP(His)6, gD-SEAP(His)6 or control SEAP(His)6 was added
to wells and incubated at room temperature for 1 h. After
washing with PBS, bound gB-SEAP(His)6, gD-SEAP(His)6,
and SEAP(His)6 were measured by alkaline phosphatase
enzymatic activity using Great EscApe Detection kit (BD
Biosciences, Mountain View, CA) and expressed as relative
light units/s.
Electron microscopy
Aliquots of HSV-1 (15 μl, 1 × 1011 PFU/ml) were treated
without or with chemokines at 1 μM at 37 °C for 1 h. HSV-1
samples were fixed with 2% glutaraldehyde (Wako, Osaka,
Japan) in PBS at 4 °C overnight. For scanning electron
microscopy, fixed HSV-1 samples were adsorbed to plastic
cover slips, which had been treated with 0.1% poly-L-lysine (M.
W. 22,100, Sigma-Aldrich, St. Luis, MO) for 5 min, washed
with water and dried. After adsorption for 1 h, virions were
further fixed with 2% glutaraldehyde in PBS, washed with
water for 10 min twice, and post-fixed with 1% osmium
tetraoxide (Nacalai-Tesque, Kyoto, Japan) in PBS at 4 °C for
1 h. Samples were rinsed twice with water and dehydrated in a
graded series of ethanol. After treatment with isoamyl acetate,
samples were dried in a critical-point drying apparatus HCP-1
(Hitachi Koki, Tokyo, Japan) with liquid carbon dioxide. Dried
samples were coated with 2-nm-thick platinum-paradium using
a magnetron sputter coater E-1030 (Hitachi, Ibaraki, Japan).
Samples were observed on a ultra-high resolution scanning
electron microscope S-900 (Hitachi Koki) with accelerating
voltage of 10 kV and actual magnifications ranging from
×100,000 to ×200,000. For transmission electron microscopy,
fixed HSV-1 samples were diluted 1:4 with distilled water and
spotted on a 150-A sheet mesh (Nissin EM, Tokyo, Japan),
which had been coated with Formvar (Nissin EM), covered by
10 nm with evaporated carbon and made hydrophilic. Excess
water was removed with filter paper and samples were
negatively stained with 2% phosphotungstic acid. Excess
fixative was removed with filter paper and samples were
observed on a transmission electron microscope H7100 (Hitachi
Koki) with accelerating voltage of 100 kV and a magnification
of ×30,000.
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